Cardiovascular Systems Inc (NASDAQ:CSII) – Research analysts at William Blair issued their Q3 2018 EPS estimates for Cardiovascular Systems in a report released on Wednesday. William Blair analyst M. Kaczor expects that the medical device company will earn ($0.03) per share for the quarter. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Cardiovascular Systems’ Q4 2018 earnings at $0.02 EPS, FY2018 earnings at ($0.08) EPS, Q1 2019 earnings at ($0.06) EPS, Q2 2019 earnings at ($0.06) EPS, Q3 2019 earnings at ($0.02) EPS and FY2019 earnings at ($0.09) EPS.
Several other equities analysts have also weighed in on the company. BidaskClub raised Cardiovascular Systems from a “sell” rating to a “hold” rating in a research note on Friday, January 26th. Needham & Company LLC lowered Cardiovascular Systems from a “buy” rating to a “hold” rating and reduced their price objective for the company from $33.11 to $23.00 in a research note on Friday, December 15th. Raymond James Financial reaffirmed a “hold” rating on shares of Cardiovascular Systems in a research note on Monday, December 4th. Zacks Investment Research raised Cardiovascular Systems from a “sell” rating to a “hold” rating in a research note on Monday, November 13th. Finally, Leerink Swann reduced their price objective on Cardiovascular Systems from $31.00 to $30.00 and set an “outperform” rating on the stock in a research note on Thursday. Three research analysts have rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $27.00.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings results on Wednesday, February 7th. The medical device company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Cardiovascular Systems had a negative return on equity of 0.51% and a negative net margin of 1.62%. The firm had revenue of $52.63 million for the quarter, compared to analyst estimates of $53.39 million. During the same period last year, the company earned $0.03 EPS. The firm’s quarterly revenue was up 5.2% on a year-over-year basis.
Large investors have recently made changes to their positions in the stock. BlueCrest Capital Management Ltd purchased a new stake in shares of Cardiovascular Systems during the 2nd quarter valued at about $204,000. Advisor Group Inc. raised its holdings in shares of Cardiovascular Systems by 0.4% during the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock valued at $263,000 after buying an additional 35 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Cardiovascular Systems by 34.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock valued at $265,000 after buying an additional 2,115 shares during the period. Teacher Retirement System of Texas purchased a new stake in shares of Cardiovascular Systems during the 4th quarter valued at about $273,000. Finally, Trexquant Investment LP purchased a new stake in shares of Cardiovascular Systems during the 3rd quarter valued at about $276,000. Institutional investors and hedge funds own 75.29% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/equities-analysts-set-expectations-for-cardiovascular-systems-incs-q3-2018-earnings-csii.html.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.